Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Immix Biopharma, Inc. - Common Stock
(NQ:
IMMX
)
2.160
+0.010 (+0.47%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Immix Biopharma, Inc. - Common Stock
< Previous
1
2
3
Next >
Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201
July 08, 2024
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum
June 17, 2024
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma
April 29, 2024
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma on Track to Dose NXC-201 Patients in United States
April 18, 2024
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial
March 20, 2024
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative
March 05, 2024
Hear from the ~30,000 relapsed or refractory AL Amyloidosis patients in the United States today in their own words
From
Immix Biopharma, Inc.
Via
GlobeNewswire
BioMedNewsBreaks — Immix Biopharma Inc. (NASDAQ: IMMX) Closes on $15M Public Offering
February 09, 2024
Via
Investor Brand Network
Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock
February 08, 2024
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis
February 07, 2024
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock
February 05, 2024
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Announces Proposed Public Offering of Common Stock
February 05, 2024
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products
January 24, 2024
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory Board
January 04, 2024
Dr. Sanchorawala co-authored landmark study of daratumumab (DARZALEX®) in AL Amyloidosis published in The New England Journal of Medicine, 2021 that led to it becoming a first-line standard of care
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Announces Dr. Marko Radic, Autoimmune CAR-T Pioneer and Associate Professor at the University of Tennessee Health Science Center, Joins Scientific Advisory Board
December 18, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Announces 100% Overall Response Rate (n=10); 23.7 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2023
December 11, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma to Present at the 2023 JMP Securities Hematology and Oncology Summit
November 30, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis
November 22, 2023
Virtual Event to be held on November 29, 2023 at 4:15 p.m. ET
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing
November 21, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 9 Relapsed/Refractory AL Amyloidosis Patients
November 06, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 63 Relapsed/Refractory Multiple Myeloma Patients
November 06, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Subsidiary Nexcella Announces Dr. Michaela Liedtke, Stanford Medicine Cancer Center Hematology Program Lead and Co-Director Stanford Amyloid Center, Joins Scientific Advisory Board
October 26, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Completes 3rd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site
October 16, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Inc. (NASDAQ: IMMX) Climbs to New 52-Week High
October 04, 2023
Via
Investor Brand Network
Immix Biopharma Announces Complete Response in 9th Relapsed/Refractory AL Amyloidosis Patient in NXC-201 Clinical Trial at IMS 20th Annual Meeting
October 03, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma
October 02, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Amyloid Light Chain (AL) Amyloidosis
September 21, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Subsidiary Nexcella Completes 2nd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site
September 19, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Nexcella, Immix Biopharma Subsidiary, to Present at the Bank of America 2023 Healthcare Trailblazers Private Company Conference
September 07, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Announces Dr. Suzanne Lentzsch, Director of the Multiple Myeloma and Amyloidosis Program at the College of Physicians and Surgeons of Columbia University and at New York Presbyterian Hospital in New York, Joins Scientific Advisory Board
September 01, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Multiple Myeloma
August 23, 2023
From
Immix Biopharma, Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.